Stay on top of Sucampo’s latest news by subscribing to our RSS feeds.
Really Simple Syndication (RSS) is a format designed for sharing web content such as headlines. An RSS feed highlights new material for you, so you don’t have to repeatedly check a site yourself for updates.
To make use of RSS, you’ll need an RSS reader, or aggregator. An RSS aggregator can be a stand-alone application, or a plug-in for another program you already use, such as Microsoft Outlook. Some web browsers, such as Firefox and Safari RSS, have RSS readers built in. There are also online aggregators, websites such as My Yahoo or Bloglines that allow you to customize them by adding RSS feeds. Find a downloadable RSS aggregator.
To view a feed in your RSS Aggregator:
Click on the RSS feed that corresponds to the topic that interests you
Copy the URL
Paste the URL into your reader
Sucampo’s most recent annual report and quarterly reports are available on our Reports and Filings page.
To request additional information, please fill out and submit the form below.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.